Parkinson's doesn't just affect movement and the brain -- it may also impact the heart, according to new research. Scientists suggest that targeting a key protein outside of the brain could help ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Roche outlined the effectiveness of digital health technologies (DHTs) in providing more sensitive measures of ...

A project led by scientists at the University of Dundee’s School of Life Sciences and School of Medicine has been selected for the 2025 SPARK NS Translational award, aimed at accelerating scientific d ...

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

AC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II ...

Trontinemab is currently being studied in the Phase Ib/IIa Brainshuttle AD study assessing the safety, tolerability, ...

Unlearn®, a leader in AI solutions for clinical trials, today announced results from a collaboration with remynd, a Belgium-based biotech company developing treatments for neurodegenerative diseases.

Adaptive deep brain stimulation has virtually eliminated the most debilitating motor symptoms for some Parkinson’s patients ...

Denali Therapeutics is advancing the fight against neurodegenerative diseases thanks to pioneering work in methods to address ...

After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, ...

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active ...